Skip to content
Search

Latest Stories

Semaglutide and rare eye condition - EMA investigates the possible link

Semaglutide eye condition
(Photo by Steve Christo - Corbis/Corbis via Getty Images)

Two recent observational studies have suggested an elevated risk of developing a rare eye condition in patients treated with semaglutide 

The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has initiated a review of semaglutide-containing medicines after concerns were raised regarding a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition.

Semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is used in the treatment of diabetes and obesity, with medicines like Ozempic, Rybelsus, and Wegovy containing the active substance.


A report from the PRAC highlighted two recent observational studies that suggest patients treated with semaglutide may face a higher risk of developing NAION.

This condition, caused by reduced blood flow to the optic nerve, can result in vision loss in the affected eye.

However, two other recent observational studies did not show an increased risk, according to the report.

EMA’s safety committee said it will now review “all available data on NAION with semaglutide including data from clinical trials, post-marketing surveillance, studies on the mechanism of action and the medical literature (including the results of the observational studies).”

PRAC also noted that patients with type 2 diabetes might already have an inherently higher risk of developing NAION.

A report published in JAMA Ophthalmology in July 2024 indicated an association between semaglutide and NAION.

The researchers analysed data over a six-year period from nearly 17,000 neuro-ophthalmology patients at Massachusetts Eye and Ear Hospital in Boston, Massachusetts, all of whom had no prior history of NAION.

They found that the incidence of NAION occurring for the first time over a 36-month period was 8.9 per cent among patients with type 2 diabetes mellitus (T2DM) who were prescribed semaglutide, compared to 1.8 per cent patients with T2DM who were prescribed other antidiabetic medications.

There were also reports suggesting a potential risk of suicidal thoughts and self-harm associated with GLP-1 receptor agonists.

However, reviews from both the EMA and the Medicines and Healthcare products Regulatory Agency (MHRA) have found no causal association between the drug and psychiatric reactions.

More For You

Hay fever treatment: Dymista nasal spray now available in pharmacies without prescription

Hay fever affects one in four people in the UK

gettyimages

Hay fever treatment: First OTC combination nasal spray launched

For the first time, a double-action combination treatment for moderate to severe hay fever has been available over the counter across UK pharmacies, offering a new option for those sufferers who remain uncontrolled on a corticosteroid or antihistamine nasal spray.

Launched by global healthcare company Viatris, Dymista® CONTROL (azelastine hydrochloride and fluticasone propionate) nasal spray— previously only available via prescription under the brand name Dymista — can be accessed without a GP visit.

Keep ReadingShow less
Nick Kaye
Nick Kaye appointed as NPA's new chair
Nick Kaye appointed as NPA's new chair

Breaking news: NPA members advised against collective action

With the government’s recent announcement of increased funding to the sector signalling a ‘clear step forward’, the National Pharmacy Association (NPA) has today announced that it will not be recommending collective action to its members.

Last month, the department of health announced the Community Pharmacy Contractual Framework (CPCF) with an increase in funding for 2024/25 of £106m to £2.7 billion and simultaneously a further increase to £3.1 billion for 25/26.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
​Pope Francis

Pope Francis at the Vatican on December 4, 2024.

Photo by FILIPPO MONTEFORTE/AFP via Getty Images

His Holiness Mahant Swami Maharaj offers condolences to Catholic community following Pope Francis' passing

His Holiness Mahant Swami Maharaj, the spiritual leader and president of the Bochasanwasi Akshar Purushottam Swaminarayan Sanstha (BAPS), has expressed heartfelt condolences to the Catholic community worldwide following the passing of Pope Francis on Monday.

In a formal letter addressed to the members of the Roman Catholic Church, Mahant Swami Maharaj conveyed the deep sorrow of the BAPS Swaminarayan Hindu fellowship, acknowledging the Pope's passing as “a profound loss to the Catholic community and Christians around the world.”

Keep ReadingShow less